Mannkind EV/EBIT MNKD

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2016.

Today, Oct 23, 2026: 103×
10-year median: 20.6×
Against its 10-year history: 89th; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.8× to 158×
Peer median: 8.5×

Mannkind's EV/EBIT is 103× as of Oct 23, 2026.

That is above its ten-year median of 20.6×, higher than on 89% of days in the last ten years.

Over that time it ranged from 2.8× in May 2017 to 158× in Mar 2024.

The median for 10 large drugmakers of a similar size is 8.5×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	103×	18.2×	129×
2025	20.4×	12.1×	32.6×
2024	34.3×	29.4×	158×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	7.6×	2.8×	11.1×
2016	8.5×	7.7×	9.0×

Against its peers

Companies in Drug Manufacturers - General nearest Mannkind's size, closest first, today.

Company	EV/EBIT
MNKDMannkind	103×
AMPHAmphastar Pharmaceuticals	12.2×
OMEROmeros	n/m
ABUSArbutus Biopharma	4.9×
COLLCollegium Pharmaceutical	9.4×
PCRXPacira BioSciences	7.6×
ANABAnaptysbio	n/m
PAHCPhibro Animal Health	11.7×
ANIPANI Pharmaceuticals	10.5×
CRMDCorMedix	2.3×
ZVRAZevra Therapeutics	2.9×
Peer median	8.5×

Where Mannkind ranks

#46of 48Large drugmakers with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Mannkind

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.